This is what my friend had to say on the matter:
I don't like this article, poorly written, plenty of inaccuracies, I feel. Too lazy to look up if it's true at all, but I would believe that there is a kernal of truth behind it all. Blocking viral entry into the cell is something that people have been working on. The mechanism of entry is known, just a matter of getting something that works.
Of course there are going to be side effect. The sample size (n=40) is very small, so this would only be a phase I trial anyway, and you're not necessarily going to see what the side effects are. Cells don't just have random proteins on their surface, so if you block one, you're going to be influencing whatever that protein's function was, which will be the cause of the side effects (and is in fact the cause of all side effects).
Just because the virus itself isn't being directly attacked does not mean that evolution and survival of the fittest ceases to act. The virus simply waits until a mutation arises whereby the virus has greater affinity for the CD4 receptor than the drug AK602 has. When the virus binds tighter than the drug, then it can gain the upper hand and enter if the mechanism of the block is reversible inhibition. If it is irreversible inhibition, than the virus could counter with an increased number of daughter viruses released by an infected cell, raising the viral load in the bloodstream in order to better compete with the drug for binding sites.
The binding site is the CD4 molecule, but that molecule comes in different flavors, and the nature of the infection changes as the virus population switches its focus from one to the other, from attacking monocytes to T cells. Does the drug protect against both? Protect equally against both? Who knows?
After a 10 day course, the article says viral load dropped to an average of 1%. 1 percent of what? One percent of their starting viral load? Everyone had different starting viral loads, I am sure. Isn't it a coincidence that they all lost different numbers of virus such that each was left with one percent of what they started with?
Who uses ounces to measure drug dosages? No one.
Oh, and it's a Japanese team doing research on US patients. That seemed weird to me as well.